

August 13, 2022

BSE LimitedPhiroze Jeejeebhoy Towers
Dalal Street

Mumbai - 400001

Scrip Code: 533320

National Stock Exchange of India Limited

Exchange Plaza
Bandra Kurla Complex

Bandra (E), Mumbai - 400051

Symbol: JUBLINDS

Sub: Unaudited Financial Results - Newspaper Publications

Dear Sirs,

Further to our letter dated August 12, 2022, regarding approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022. Please find enclosed newspaper advertisements published, in compliance with Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, in <u>MINT</u> (English) and <u>HINDUSTAN</u> (Hindi) on August 13, 2022.

This is for information and records.

Thanking you,

Yours faithfully, For Jubilant Industries Limited

Abhishek Mishra Company Secretary

A Jubilant Bhartia Company





J&J to stop talc powder sales globally in 2023

Move comes years after firm pulled product in US, Canada amid continued lawsuits

feedback@livemint.com

ohnson & Johnson said it plans to stop selling its legacy talc-based baby-powder products globally in 2023, a move that comes amid continued legal battles and years after the company discontinued the product in the US and Canada.

J&J said Thursday that it had made the "commercial decision" to transition all its baby powder products to use cornstarch instead of talcum powder after conducting an assessment of its portfolio. The health conglomerate, which maintains the product is safe, has for almost a decade faced lawsuits accusing it of hiding cancer risks tied to its talc-based baby powder.

"We continuously evaluate and optimize our portfolio to best position the business for long-term growth," spokesperson Melissa Witt said in an emailed statement, "Today's decision is part of a worldwide portfolio assessment, which evaluated several factors, including differences in demand for our products across geographic regions and evolving consumer trends and preferences.'

Shares of the New Brunswick, New Jersey-based company rose less than 1% in post-market trading and had fallen 2.3% so far this year through Thursday's close.

In May 2020, as J&J navigated thousands of lawsuits accusing the product of causing some users' cancers, the company pulled its talc-based powders from the US and Canadian markets, citing another "commercial decision" based on declining

"After decades of selling talc-based products the company knew could cause deadly cancers to unsuspecting women and men around the world, J&J has finally done the right thing," Leigh O'Dell, a lawyer for former talc users, said in an emailed statement Thursday. "They



J&J had sought bankruptcy protection for its newly created LTL Management LLC unit last year after arguing it was struggling to contain the lawsuits

stopped sales in North America more than two years ago. The delay in taking this step is inexcusable.

Talcum powder has long been used in baby products because the mineral keeps skin dry and prevents diaper rash. The

mines that produce the powder, however, **TAKING A POWDER**

IN May 2020, J&J pulled out its talc-based powders

THE health **THE** company put conglomerate faces 40,300 lawsuits in \$2 billion into a trust as part of the unit's the US over its talcresolve all talc claims

can also yield asbestos, a mineral once used in products such as building insulation that researchers have linked to cancers. Some consumer companies have found corn starch can offer the same ben-

efits of talc without the asbestos risk. J&J said Thursday that its "position on the safety of our cosmetic talc remains unchanged."

The health conglomerate has spent years seeking ways to contain its legal liabilities. It faces 40,300 lawsuits in the US over its talc-based powders, according to a company filing last month with the U.S. Securities and Exchange Commission.

J&J sought bankruptcy protection for its newly created LTL Management LLC unit last year after arguing it was struggling to contain the lawsuits. $The \, company \, put \, \$2 \, billion$

into a trust as part of the unit's bankruptcy to resolve all current and future talc claims. In February, a judge said the case could proceed in order to seek settlements, but his ruling is being appealed.

Lawyers for former talc users have challenged J&J's move to have the unit seek Chapter II protection to deal with the talc

(₹ in Lakhs)

Canada Pension Plan co-invests around \$204 mn in India in April-June quarter

ranjani.raghavan@livemint.com

NEWS

anada Pension Plan Investment Board has co-invested around \$204 million along with its private equity partners in India during the June quarter, according to the pension fund's quarterly filing.

CPPIB made investments in chemicals firm Sajjan India, insuretech unicorn Acko and non-bank lender Kogta Financial (India) Ltd, it added.

CVC Capital acquired the agro chemicals business of Sajjan India in February for \$700 million, out of which, CPPIB paid \$120 million to pick up a 17% stake, it said in its quarterly report on Thursday. CPPIB's investment in Sajjan India was not publicly reported thus far.

The pension fund acquired a 5% stake for \$50 million in Acko and a 9% stake for \$34 million in Kogta Financial (India) as part of the transactions led by Multiples Private Equity. CPPIB is a general partner in several funds managed



The pension fund has also acquired a 5% stake in Acko and a 9% stake in Kogta Financial (India).

by Multiples. It also invested \$333 million as a limited partner in Sequoia Capital's Asia Pacific fundraising, including funds for China, India and Southeast Asia. However, it did not provide a country-wise split. The pension fund also backed Baring Private Equity Asia's with a \$100 million credit investment for its \$800 million buyout of IGT Solutions.

In June, Sequoia had said that it had raised \$2.85 billion, of which \$2 billion was for investments in India and \$800 million was for startups in Southeast Asia. Sequoia Capital has raised \$9 billion across four funds for investing in China. Bloomberg reported last week. CPPIB also invested \$150 million in NewQuest Capital's latest fund. Secondaries investor NewQuest Capital is owned by the TPG Group, and typically invests one-third of its corpus in India across companies and private equity funds.

Meanwhile, CPPIB reported

a net loss of \$23 billion and a negative 4.2% for fund returns in the first quarter.

'Financial markets experienced the most challenging first six months of the year in the last half century, and the fund's first fiscal quarter was not immune to the widespread decline. However, our active management strategy - diversified across asset classes and geographies - moderated the impact on the fund, preserving investment value," John Graham, president and chief exec utive, said in a statement.

"The uncertain business and investment conditions we noted in the previous quarter continues, and we expect to see this persist throughout the fiscal year. Our resilient portfolio is designed to create value over the very long term as demonstrated by our continued strong 10-year net return, even as we expect to experience doubledigit percentage losses."

The results were driven by losses in public equity strategies, due to the broad decline in equity markets, it added.

Samsung heir wins presidential pardon

Bloomberg

feedback@livemint.com

amsung Electronics Co. Vice Chairman Jay Y. Lee won a presidential pardon from graft charges, allowing him to formally take the helm of an electronics conglomerate roiled by global demand and supply shocks.

South Korean President Yoon Suk Yeol cleared the heir to the country's biggest company of bribery charges, for which Lee spent 18 months in prison before his release on parole a year ago. Samsung's shares rose 1.3% in Seoul.

The decision clears the way for Korea's most prominent business scion to officially take the reins of the world's biggest

smartphonesmak. Lee's return is regarded as a stabilizing force for a Korean economy buffeted by inflation, market disruption from the Ukraine war and

logistics snarls triggered by China's Covid lockdowns. Rising tensions between the US and China over chip technology also

complicate long-term plans for Samsung.

Lee apologized to the Korean public on Friday and promised to "start

anew." "I will try The decision harder to give clears the way for back to society Samsung vice and grow together," Lee chairman Jay Y. Lee to officially said in a statetake the reins of ment. The

the company 54-year-old Lee has been granted a special pardon effective as of August 15, the country's independence anni-

versary. He had initially been

sentenced to 30 months for

alleged attempts to bribe a sitting president and win government support for his suc-

The reinstatement will allow him to rejoin the board at the tech giant as well as travel overseas for deals. "Samsung's in a crisis as it

has lost its two strengths: technology leadership and strict management," said Park Ju-gun, head of corporate research at Leaders Index. "There's an absence of a control tower making the right decisions at the right time to keep its leadership in the semiconductor industry."



Jubilant Industries Limited

Registered Office: Bhartiagram, Gajraula, Distt. Amroha - 244 223 (U.P.) | CIN: L24100UP2007PLC032909 Website: www.jubilantindustries.com | E-mail: investorsjil@jubl.com | Ph.: +91-5924-267200

Extract of Consolidated Unaudited Financial Results for the Quarter Ended 30th June 2022

	(KIII EAKIS)					
			Year Ended			
SI No.	Particulars	June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1.	Total Revenue from operations	35,503	32,920	21,151	116,580	
2.	Net Profit/(Loss) for the period (before tax and Exceptional items) from continuing operations	2,769	177	2,743	7,342	
3.	Net Profit/(Loss) for the period before tax (after Exceptional items) from continuing operations	2,769	177	2,743	7,342	
4.	Net Profit/(Loss) for the period after tax and Exceptional items from continuing operations	2,170	(116)	2,185	5,461	
5.	Net Profit/(Loss) for the period from discontinued operations	33	(22)	(42)	(103)	
6.	Net Profit/(Loss) for the period from continuing operations and discontinued operations		(138)	2,143	5,358	
7.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,198	(101)	2,153	5,391	
8.	Equity Share Capital	1,507	1,503	1,503	1,503	
9.	Reserves excluding Revaluation Reserve				12,469	
10.	Earnings per share of ₹ 10 each from continuing operations					
	(a) Basic (₹)	14.43	(0.78)	14.54	36.33	
	(b) Diluted (₹)	14.29	(0.87)	14.45	35.93	
	Earnings per share of ₹ 10 each from discontinued operations					
	(a) Basic (₹)	0.22	(0.14)	(0.28)	(0.68)	
	(b) Diluted (₹)	0.22	(0.14)	(0.28)	(0.68)	
	Earnings per share of ₹ 10 each from continuing operations and discontinued operations					
	(a) Basic (₹)	14.65	(0.92)	14.26	35.65	
	(b) Diluted (₹)	14.51	(1.01)	14.17	35.25	

Place: Gurugram

Date: 12th August, 2022

1. The Standalone Financial Results are available under Investors section of our website at www.jubilantindustries.com and under Financial Results at Corporates section of www.nseindia.com and www.bseindia.com. Key Standalone Financial information of the Company is as

(Cili Lakis)						
SI No.	Particulars		Year Ended			
		June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1.	Total Revenue from operations	-	-	-	-	
2.	Profit/(Loss) for the period before tax from continuing operations	-	-	-	-	
3.	Net Profit/(Loss) for the period after tax from continuing operations	-	-	-	-	
4.	Net Profit/(Loss) for the period from discontinued operations	33	(20)	(40)	(94)	
5.	Net Profit/(Loss) for the period from continuing operations and discontinued operations	33	(20)	(40)	(94)	

- 2. The above unaudited financial results were, reviewed by the Audit Committee and approved and taken on records by the Board of Directors at its meeting held on 12th August, 2022.
- 3. The above is an extract of the detailed format of the unaudited consolidated financial results for the quarter ended June 30, 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited consolidated & standalone financial results for the quarter ended June 30, 2022 alongwith review report of the Statutory Auditors is available under Investors section of our website at www.jubilantindustries.com and under Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

for Jubilant Industries Limited

Manu Ahuja **CEO & Managing Director**





ONGC Energy Soldiers have put our *Tiranga* on the world map Be it in Oil and Gas or Commonwealth Games 2022

Extract of Financial Results for the Quarter Ended 30 June 2022 (₹ in (rore unless otherwise stated) Standalone Year Quarter Quarter Quarter Quarter Year ended 31.03.2022 ended 30.06.2022 **Particulars** No. Unaudited 42,320.72 23,021.64 1,10,345.40 1,82.893.75 1,08,104.87 5,31,761.83 Total Income from Operations Net Profit / (Loss) for the period 20,342.97 6,750.17 41,039.99 12,894.25 10,194.43 56,196.02 (before Tax, Exceptional items) Net Profit / (Loss) for the period before Tax 20.342.97 6.750.17 41.039.99 12.220.59 10.194.43 54.091.11 Net Profit / (Loss) for the period after Tax 15,205.85 4.334.75 40,305.74 8.580.75 6.846.79 49,294.06 (after Exceptional items) Total Comprehensive Income for the period (Comprising Profit / (Loss) 13.682.32 6.596.95 44.037.65 13.142.99 10.000.85 53.691.32 Other Comprehensive Income (after tax)1 Equity Share Capital (Face value of 6,290.14 6,290.14 Net worth 2.50.830.39 2.11.155.51 2.37.148.09 Paid up Debt Capital / Outstanding Debt 9,090.23 11,513.50 6,396.90 2.53.212.77 Other Equity 2.44.540.25 2.04.865.37 2.30.857.95 10 Debenture Redemption Reserve Not applicable Not applicable Not applicable Earnings Per Share (Face value of ₹ 5/- each)- not annualised 12.09 3.45 (b) Diluted (₹) 12.09 3.45 32.04 9.49 4.76 Debt Equity Ratio 0.04 0.05 0.03 290.52 Debt Service Coverage Ratio 79.86 142.18 14 290.52 142.18 Interest Service Coverage Ratio 79.86

Notes:

Place: New Delhi

Dated: 12 August 2022

1) The above results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act. 2013. read with the relevant rules issued thereunder and other accounting principles generally accepted in India

The above is an extract of the detailed format of unaudited Financial Results for quarter ended 30.06.2022 filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of unaudited Financial Results for the quarter ended 30.06.2022 are available on the Stock Exchanges website of BSE (www.bseindia.com), NSE (www.nseindia.com) and Company's website at www.ongcindia.com

By order of the Board

(Pomila Jaspal)

Oil and Natural Gas Corporation Limited



Tel: 011-26754002, Fax: 011-26129091, E-mail: secretariat@ongc.co.in

www.ongcindia.com 🚹 /ONGCLimited 💟 @ONGC_ Linked in /company/ONGC 📵 Youtube: ONGC Ltd 💿 Instagram/ongcofficial 🐥 @ONGC_

जुलाई में खुदरा महंगाई करीब चौथाई फीसदी घटी, थम सकती है रेपो दर में वृद्धि

महंगाई नरम : कर्ज की बढ़ती

किस्त पर लग सकती है लगाम

नई दिल्ली, हिन्दुस्तान ब्यूरो। महंगाई पर अंकुश के लिए रिजर्व बैंक की ओर रेपो दर बढाने और सरकार की कोशिशों का असर दिखना शरू हो गया है। इस साल जुलाई में खुदरा महंगाई जून के मुकाबले करीब चौथाई फीसदी घटी है। वहीं खाद्य महंगाई करीब एक फीसदी घटी है।

इसके साथ ही पिछले चार माह से खुदरा महंगाई में नरमी दिख का रुख देखने को मिल रहा है। विशेषज्ञों का मानना है कि महंगाई में नरमी से रिजर्व बैंक आने वाले समय में रेपो दर में वद्धि को रोक सकता है। आरबीआई रेपो दर में वृद्धि को रोकता है तो पिछले तीन माह से कर्ज की बढ़ती मासिक किस्त से उपभोक्ताओं को राहत मिल सकती है। रिजर्व बैंक ने मई में महंगाई पर अंकुश के लिए अचानक रेपो दर में 0.50 फीसदी का इजाफा कर दिया था।

6.75 प्रतिशत रही खाः महंगाई जुलाई में

प्रतिशत थी खाद्य महंगाई जुन में

उपभोक्ताओं संग आरबीआई को भी राहत रिजर्व बैंक रेपो दर का आकलन

करने के लिए खुदरा महंगाई को मानक मानता है। इसमें कमी आने या संतोषजनक स्तर पर रहने की स्थिति में आरबीआई रेपो दर में कटौती करता है जिसके बाद बैंक कर्ज सस्ता करते हैं। इससे आम लोगों को घर, कार खरीदने से लेकर अन्य तरह के कर्ज सस्ते हो जाते हैं। महंगाई ऊंची होने से पिछली तीन बार से रिजर्व बैंक को रेपो दर बढ़ाने पर मजबूर होना



सस्ता कच्चे तेल का भी जल्द दिखेगा असर

कच्चे तेल के दाम में पिछले तीन माह में 18 फीसदी से अधिक गिरावट आ चकी है। यह 100 डॉलर प्रति बैरल से नीचे पहुंच गया है। आईआईएफल के उपाध्यक्ष अनुज गुप्ता ने हिन्दुस्तान को बताया कि कच्चे र्तल के सस्ते होने से कंपनियों की लागत घटेगी जिससे पेट्रोल-डीजल के दाम में कमी आ सकती है।

इसलिए जगी आस

- 1. महंगाई के नरम रुख से आरबीआई के लिए रेपो दर पर फैसला लेना आसान होगा
- 2. आर्थिक वृद्धि दर में तेजी से उद्योगों को रोजगार सृजन में मदद मिलेगी
- 3. खाद्य वस्तुओं संग अन्य उत्पाद के दाम घटने से आरबीआई आने वाले समय में दरें घटाने पर कर सकता है विचार



SCAN THIS OR CODE TO BOOK YOUR TICKETS NOW



farnazfever

हिन्दुस्तान भरोसा नए हिन्दुस्तान का



मिलिए अपनी डिजिटल अन्तिर

आपकी अनोखी अब हो गयी है फ्री डिजिटल पर, प्यार और भरोसा है वही पहले वाला। तो हर शनिवार कीजिये इस से डिजिटल मुलाकात।



फ्री अनोखी पढ़ने के लिए QR कोड स्कैन करें या 7065115544 पर मिस्ड कॉल दें।





Jubilant Industries Limited

Registered Office: Bhartiagram, Gajraula, Distt. Amroha - 244 223 (U.P.) | CIN: L24100UP2007PLC032909 Website: www.jubilantindustries.com | E-mail: investorsjil@jubl.com | Ph.: +91-5924-267200

Extract of Consolidated Unaudited Financial Results for the Quarter Ended 30th June 2022

(₹ in Lakhs)					
	Particulars	Quarter Ended			Year Ended
SI No.		June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	Total Revenue from operations	35,503	32,920	21,151	116,580
2.	Net Profit/(Loss) for the period (before tax and Exceptional items) from continuing operations	2,769	177	2,743	7,342
3.	Net Profit/(Loss) for the period before tax (after Exceptional items) from continuing operations	2,769	177	2,743	7,342
4.	Net Profit/(Loss) for the period after tax and Exceptional items from continuing operations	2,170	(116)	2,185	5,461
5.	Net Profit/(Loss) for the period from discontinued operations	33	(22)	(42)	(103)
6.	Net Profit/(Loss) for the period from continuing operations and discontinued operations	2,203	(138)	2,143	5,358
7.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,198	(101)	2,153	5,391
8.	Equity Share Capital	1,507	1,503	1,503	1,503
9.	Reserves excluding Revaluation Reserve				12,469
10.	Earnings per share of ₹ 10 each from continuing operations				
	(a) Basic (₹)	14.43	(0.78)	14.54	36.33
	(b) Diluted (₹)	14.29	(0.87)	14.45	35.93
	Earnings per share of ₹ 10 each from discontinued operations				
	(a) Basic (₹)	0.22	(0.14)	(0.28)	(0.68)
	(b) Diluted (₹)	0.22	(0.14)	(0.28)	(0.68)
	Earnings per share of ₹ 10 each from continuing operations and discontinued operations				
	(a) Basic (₹)	14.65	(0.92)	14.26	35.65
	(b) Diluted (₹)	14.51	(1.01)	14.17	35.25

1. The Standalone Financial Results are available under Investors section of our website at www.iubilantindustries.com and under Financia Results at Corporates section of www.nseindia.com and www.bseindia.com. Key Standalone Financial information of the Company is as

٠.	Particulars	Quarter ended			Year Ended
SI No.		June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022
140.		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	Total Revenue from operations	-	-	-	-
2.	Profit/(Loss) for the period before tax from continuing operations	-	-	-	-
3.	Net Profit/(Loss) for the period after tax from continuing operations	-	-	-	-
4.	Net Profit/(Loss) for the period from discontinued operations	33	(20)	(40)	(94)
5.	Net Profit/(Loss) for the period from continuing operations and discontinued operations	33	(20)	(40)	(94)

- 2. The above unaudited financial results were, reviewed by the Audit Committee and approved and taken on records by the Board of Directors at its meeting held on 12th August, 2022.
- 3. The above is an extract of the detailed format of the unaudited consolidated financial results for the quarter ended June 30, 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited consolidated & standalone financial results for the quarter ended June 30, 2022 alongwith review report of the Statutory Auditors is available under Investors section of our website at www.jubilantindustries.com and under Financial Results at Corporates section of www.nseindia.com and www.bseindia.com

for Jubilant Industries Limited

Manu Ahuja **CEO & Managing Director**



Date: 12th August, 2022

Place: Gurugram

अखिल भारतीय आयुर्विज्ञान संस्थान, नागपुर ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NAGPUR

प्लॉट क्र. 2, सेक्टर-20, मिहान, नागपुर - 441108 वेबसाईट: http://aiimsnagpur.edu.in

विज्ञापन संख्या : एम्स/नागपुर/एडमिन-1/ फॅकल्टी/2022/02

एम्स नागपुर के विभिन्न विभागों में फेकल्टी (समृह ए) के पदों की सीधी भर्ती/प्रतिनियुक्ति/अनुबंध के आधार पर, चयन हेतु विज्ञापन प्रारंभिक तिथि : 13/08/2022 | अंतिम तिथि : 11/09/2022

पीएमएसएसवाय के अंतर्गत स्थापित एम्स नागपुर, जिसका उद्देश्य, क्षेत्रीय स्तर पर उपलब्ध अफोर्डेबल / विश्वसनीय जन स्वास्थ सेवाओं के असंतुलन में सुधार लाकर, देश में, चिकित्सा शिक्षा के स्तर की गुणवत्ता को बढ़ाना है। संस्थान ने सत्र 2018-19 से कार्य करना प्रारंभ किया है।

एम्स नागपुर की एक उच्च स्तरीय शिक्षण, प्रशिक्षण व शोध संस्थान के रूप में विकसित करने की परिकल्पना की गई है। इस तारतम्य में. निदेशक ऍम्स नागपर द्वारा भारतीय नागरिकों/नागरिकता अधिनियम 1955 के 7ए सेक्शन के अंतर्गत भारत के ओवरसीज सिटीजन कार्ड धारक के रूप में पंजीकृत व्यक्तियों से, निम्न फेकल्टी (नए और बैकलॉग) के नियमित पदों के लिए सीधे नियुक्त किये जाने हेत् आवेदन आमंत्रित किये जाते है -

अनु	विषय	प्राध्यापक	अतिरिक्त	सहयोगी	सहायक		
क्र.	14.1	20.5 00.00	प्राध्यापक	प्राध्यापक	प्राध्यापक		
1.	एंडोक्रिनोलॉजी और मेटाबॉलिज्म*	-	01 (एससी)	01 (ओबीसी)#	01 (एसटी)#		
2.	गॅस्ट्रोएन्टेरोलॉजी (मेडिकल)*	-	01 (अनारक्षित)#	-	01 (ई.डब्ल्यू.एस.)#		
					01 (ओबीसी)#		
3.	मेडिकल हेमॅटोलॉजी*	-	01 (अनारक्षित)	-	-		
4.	मेडिकल ऑन्कोलॉजी*	01 (अनारक्षित)	-	-	-		
5.	न्युनॅटोलॉजी*	-	01 (एससी)	-	-		
6.	नेफ्रोलॉजी*	01 (ओबीसी)#	-	01 (एससी)#	-		
7.	न्यूरोलॉजी*	-	01 (अनारक्षित)#	01 (ओबीसी)#	-		
8.	न्यूरोसर्जरी*	01 (अनारक्षित)	-	-	02 (अनारक्षित)#		
9.	न्यूक्लियर मेडिसिन	-	01 (ओबीसी)	-	-		
10.	पेडीयाट्रीक सर्जरी*	-	01 (अनारक्षित)	-	-		
11.	साइकेट्री	01(ई.डब्ल्यू.एस.)	-	-	-		
12.	पल्मोनरी मेडिसिन*	-	-	-	01 (ओबीसी)#		
13.	रेडियोथेरेपी	01 (अनारक्षित)	-	-	-		
14.	सर्जिकल गॅस्ट्रोएंटेरॉलॉजी*	01 (ओबीसी)	-	01 (ओबीसी)#	-		
15.	सर्जिकल ऑन्कोलॉजी*	-	01 (ओबीसी)	01 (अनारक्षित)#	-		
16.	ट्रान्सफ्युजन मेडिसिन अँड ब्लड बँक	-	01(ई.डब्ल्यू.एस.)#	-	-		
17.	ट्रॉमा अँड इमरजेंसी	01 (एससी)#	-	-	01 (एससी)#		
18.	युरोलॉजी*	01 (अनारक्षित)#	-	-	-		
कुल		08	09	05	07		
	कुल योग	29 पद					

1. 07 पद (6 बैकलॉग सहित) शारीरिक विकलांग व्यक्ति (पीडब्ल्यूडी) क्षैतिज आरक्षण हेतु पद आरक्षित रखे गये है। विज्ञापन का प्रारूप, आयु सीमा, अनिवार्य योग्यताएँ तथा अनुभव तथा वेतनमान आदि तथा आवेदन शुल्क के अग्रिम भुगतान की लिंक संबंधित विवरण वेबसाइट http://aiimsnagpur.edu.in/recruitment_notices पर उपलब्ध है। इच्छुक प्रत्याशी जो सभी योग्यता मापदंडो को पूरा करते है, अपना आवेदन गूगल लिंक के माध्यम से दिनांक 11-09-2022 तक तथा स्पीड/पंजीकृत पोस्ट द्वारा प्रति निदेशक, एम्स नागपुर, प्रशासनिक भवन, प्लाट न 2, सेक्टर-20, मिहान, नागपुर - 441108 के पते पर **26-09-2022** तक जमा कर सकते है।

निर्देशक, एम्स नागपुर





